SkinBioTherapeutics Acquires Bio-Tech Solutions Ltd for £1.25 Million

October 11, 2024 09:27 AM BST | By Team Kalkine Media
 SkinBioTherapeutics Acquires Bio-Tech Solutions Ltd for £1.25 Million
Image source: ID 67414612 © Denisfilm|Megapixl.com

Highlights

  • SkinBioTherapeutics has acquired Bio-Tech Solutions Ltd for £1.25 million.
  • The deal will be financed through a combination of a £950,000 loan from a shareholder, a subscription for new shares raising £250,000, and the use of the company's cash reserves.
  • Following a successful fundraising round in August 2024, SkinBioTherapeutics maintains a strong financial position with a cash reserve of £1.9 million.

SkinBioTherapeutics plc (LSE:SBTX), a life science company dedicated to skin health, has announced the acquisition of Bio-Tech Solutions Ltd (BTS) for a total enterprise consideration of £1.25 million. This acquisition marks the second step in the Group's M&A strategy, enhancing its capabilities in manufacturing and packaging health, hygiene, and personal care products, as well as advancing the development of topical creams.

Details of the Acquisition

  • Acquisition Terms: The total consideration for BTS will be paid in cash upon closing, which is expected shortly. Funding for the acquisition is structured through:
    • A £950,000 loan from an existing shareholder.
    • A subscription for 2,349,624 new Ordinary Shares priced at 10.64 pence, raising £250,000.
    • Utilization of the Group's cash reserves.
  • About Bio-Tech Solutions:
    • Founded by Ian Moulds, BTS is a well-established manufacturer located in Driffield, Yorkshire.
    • The company specializes in producing liquids, topical creams, lotions, tablets, and capsules, adhering to Good Manufacturing Practice (GMP) standards.
    • BTS is ISO 9001-2015 and ISO 13485-2016 certified, ensuring high quality in its operations, which include manufacturing, packaging, formulation, and regulatory affairs.
    • The firm has 23 employees involved in various essential functions.
  • Financial Performance: BTS generated £2.1 million in revenue and £0.5 million in EBITDA for the year ending June 30, 2024. Management forecasts pro forma revenue of £3.0 million and EBITDA of £0.9 million for the 2024/25 financial year. The Group anticipates cost synergies from the acquisition, particularly in the production of Dermatonics products.

Financing the Acquisition

The financing for this acquisition is designed to preserve SkinBioTherapeutics' cash runway while allowing for the integration of BTS and the realization of synergies:

  • Debt and Equity Financing: The acquisition will be financed primarily through a loan and equity contributions from long-term shareholder David Brierwood, which aids in conserving cash reserves.
  • Cash Reserves: As of the end of September 2024, the Group's cash position stood at £1.9 million. Following the acquisition, SkinBioTherapeutics maintains sufficient cash runway to support operations through to Summer 2026 without additional income from Croda or other joint development agreements.

Financial Update

Following a successful fundraising in August 2024, the Group's financial position remains strong, allowing for continued operations and investment in growth:

  • Forecasts and Revenue Expectations: The Group has not modified its revenue forecasts despite the acquisition. It remains reliant on successful commercial discussions with Sederma (part of Croda plc), which recently completed clinical studies and is moving towards full commercialization. Management emphasizes that any revenue forecasts are contingent upon the outcomes of these discussions scheduled for October and November.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next